UPB - Phase III Respiratory Franchise Expansion And Quarterly Dosing Will Support Long Term Upside Potential
Analysts believe Upstream Bio's verekitug, currently in Phase III for severe asthma and chronic rhinosinusitis with nasal polyps, has significant multi-indication potential in respiratory diseases, including COPD. Despite an anticipated revenue decrease, analysts project substantial profit margin improvement by 2029, suggesting the company is undervalued. However, risks include the successful execution of Phase III trials and achieving ambitious profitability targets to justify the high implied future P/E ratio.
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Rating of "Hold" from Analysts
Upstream Bio, Inc. (NASDAQ:UPB) has received an average rating of "Hold" from analysts, with four buy recommendations, two hold, and one sell, and an average 12-month price target of $29.67. The company's shares opened at $5.34, near their 12-month low, and the biopharmaceutical firm recently reported a quarterly loss of $0.73 per share, which was better than expected. Institutional investors, including Norges Bank and BlackRock, have recently established positions in UPB.
Houghton Adam Disposes of 700 Upstream Bio Shares at $5.49 Each
Houghton Adam sold 700 shares of Upstream Bio (NASDAQ:UPB) at $5.49 each on September 16, 2026, as recorded under an SEC transaction code S. This sale represented approximately 3.0% of his prior holdings in the company. After the transaction, Houghton Adam retained 22,901 shares of Upstream Bio, offering insights into insider share movements for investors.
Upstream Bio (UPB) exec offloads shares to cover taxes
Upstream Bio's Chief Business Officer, Adam Houghton, sold 700 shares of common stock at $5.49 per share on September 16, 2026. This transaction was an automatic "sell-to-cover" sale to satisfy tax withholding obligations related to the vesting of restricted stock units, and was not discretionary. Following the sale, Houghton directly holds 22,901 shares of UPB.
Upstream Bio Reports Phase 2 VALIANT Trial Results Showing Verekitug Reduced Severe Asthma Exacerbations by 56% with Quarterly Dosing
Upstream Bio announced positive Phase 2 VALIANT trial results for verekitug, a severe asthma treatment, showing a 56% reduction in annualized asthma exacerbation rates with quarterly dosing. The drug also improved lung function and inflammatory biomarkers. The company plans to initiate Phase 3 trials in severe asthma and chronic rhinosinusitis with nasal polyps in Q1 2027, evaluating a higher 400 mg quarterly regimen.
Upstream Bio Presents Results from the Phase 2 VALIANT
Upstream Bio presented positive results from its Phase 2 VALIANT trial for verekitug, an investigational treatment for severe asthma, at the ERS Congress 2026. The study showed verekitug reduced annualized asthma exacerbation rates by 56% and improved lung function and inflammatory biomarkers with quarterly dosing. The company plans to initiate Phase 3 trials in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in Q1 2027, aiming for best-in-class efficacy with convenient at-home administration.
Upstream Bio Number of Employees 2026 | Employee Count & Headcount Data
Upstream Bio, Inc. (UPB) reported approximately 79 total employees worldwide as of March 2026, marking a 130.0% growth from 34 employees in 2023. The company, headquartered in Waltham, Massachusetts, is actively hiring with 4 job postings in 2026, and its workforce is primarily concentrated in North America (97.5%). The average salary at Upstream Bio is $175,396, with the highest median salary in North America at $176,000.
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
Upstream Bio (Nasdaq: UPB) has announced pivotal Phase 3 development plans for its TSLP receptor antagonist, verekitug, targeting both severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Following FDA meetings, the company plans to conduct one placebo-controlled Phase 3 trial for each indication, evaluating a 400 mg subcutaneous regimen every 12 weeks in approximately 1,500 patients. The trials are set to begin in Q1 2027, with potential U.S. launch as early as 2030, pending supportive data and BLA submissions.
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
Upstream Bio is advancing its drug verekitug into pivotal Phase 3 trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in Q1 2027. Following productive discussions with the FDA, the company plans to evaluate a 400 mg dose administered every 12 weeks, aiming for best-in-class efficacy for patients irrespective of biomarker status. Verekitug, a TSLP receptor antagonist, has shown promising Phase 2 results and is expected to have a Biologics License Application submitted by 2030, potentially leading to its launch.
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
Upstream Bio has announced its pivotal Phase 3 development plans for verekitug, a novel TSLP receptor antagonist, in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Following productive discussions with the FDA, the company plans to initiate one placebo-controlled Phase 3 trial for each indication in Q1 2027, evaluating a 400 mg dose administered every 12 weeks. Upstream Bio aims to demonstrate best-in-class efficacy with convenient quarterly dosing and expects potential launch as early as 2030, pending supportive Phase 3 results and regulatory approval.
Upstream Bio reports Q2 2026 net loss $39.7M, cash and short-term investments $261.3M
Upstream Bio reported a Q2 2026 net loss of $39.7 million, with $261.3 million in cash and short-term investments. The company is on track to start Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027 and has completed enrollment for its Phase 2 COPD trial, with data expected in late 2027. They also highlighted over 500 participants treated with verekitug across programs and upcoming clinical presentations.
UPB Should I Buy
Upstream Bio Inc (UPB) is not considered a strong buy due to significant net losses and declining stock performance, despite positive clinical trial developments. The company reported a net loss of $39.7 million in Q2 2026, though cash reserves of $261.31 million are expected to fund operations through 2027. Analysts maintain a "Buy" rating but have lowered price targets, citing concerns about cash runway and the need for future equity raises.
Norges Bank Initiates New Position in Upstream Bio Inc (UPB) with 4.2 Million Share Purchase
Norges Bank has initiated a new position in Upstream Bio Inc (UPB) by acquiring over 4.2 million shares, representing a 7.73% stake in the clinical-stage biotechnology company. This move, disclosed via a 13DG filing, signals a calculated, long-term commitment despite Upstream Bio's early-stage, pre-revenue status and recent stock decline. The investment suggests Norges Bank is making a high-risk, high-reward bet on the success of Upstream Bio's lead candidate, verekitug, for inflammatory diseases.
Walleye Capital LLC Invests $3.45 Million in Upstream Bio, Inc. $UPB
Walleye Capital LLC has invested $3.45 million in Upstream Bio (NASDAQ:UPB), acquiring a 0.92% stake. This investment comes as Upstream Bio continues to be unprofitable, though it recently beat earnings and revenue estimates. Analyst sentiment is mixed, with a consensus "Hold" rating despite varying buy and sell recommendations and a projected full-year loss.
Upstream Bio (NASDAQ:UPB) Lowered to "Strong Sell" Rating by Wall Street Zen
Wall Street Zen has downgraded Upstream Bio (NASDAQ:UPB) to a "Strong Sell" rating from "Sell," intensifying cautious sentiment around the clinical-stage biotech company. Despite the downgrade, analyst opinions remain mixed, with four "Buy" ratings, two "Hold," and one "Sell," resulting in a consensus "Hold" rating and an average price target of $29.67. Upstream Bio shares are trading near their 52-week low, and the company continues to report losses, although it slightly beat recent quarterly EPS and revenue estimates.
Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co.
JPMorgan Chase & Co. has raised its price target for Upstream Bio (NASDAQ:UPB) to $9.00 from $8.00, maintaining a "neutral" rating. This new target suggests a potential upside of 29.22% from the stock's current price of $6.96. The company recently reported a quarterly loss of $0.73 per share, beating analyst estimates, and revenue of $0.77 million, exceeding expectations.
Truist Financial Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $25
Truist Financial has reiterated its Buy rating for UpStream Bio (UPB.US) and maintained its target price at $25. This indicates the firm's continued positive outlook on the company's stock performance.
A Quick Look at Today's Ratings for UpStream Bio(UPB.US), With a Forecast Between $19 to $36
This article provides a quick look at today's analyst ratings for UpStream Bio (UPB.US), noting a forecast price range between $19 and $36. It indicates that these ratings are based on the average price targets set by various financial analysts.
Upstream Bio (UPB) Earnings Date and Reports 2026 $UPB
Upstream Bio (UPB) announced its Q2 2026 earnings on August 11, 2026, reporting an EPS of -$0.73, beating analyst estimates by $0.01. The company also exceeded revenue expectations with $0.77 million against an estimated $0.56 million. Despite beating estimates, Upstream Bio's earnings are projected to decrease in the next year, from ($2.87) to ($2.89) per share.
Upstream Bio (NASDAQ:UPB) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS
Upstream Bio (NASDAQ:UPB) announced its quarterly earnings, reporting an adjusted loss of $0.73 per share, surpassing analyst expectations of a $0.78 loss by $0.05. The company also exceeded revenue forecasts, reaching $0.77 million against an expected $0.43 million. Despite beating estimates, Upstream Bio remains financially challenged with negative return on equity and net margin, and its stock price is near its 52-week low, leading to a consensus "Hold" rating from analysts.
Upstream Bio posts corporate presentation highlighting verekitug Phase 3 plans in severe asthma, CRSwNP
Upstream Bio has released a corporate presentation detailing its plans for verekitug, a TSLP receptor antagonist, including a mid-2026 FDA meeting and Phase 3 trials in severe asthma and CRSwNP targeting Q1 2027. The company's pipeline shows promising Phase 2 data for verekitug in both conditions, with operations funded through 2027. Additionally, enrollment for the COPD Phase 2 VENTURE study is complete, with data expected in H2 2027.
Form 8K Upstream Bio Inc For: 11 August By Investing.com
This article announces that Upstream Bio Inc. has filed a Form 8K on August 11, with its stock symbol UPB showing a 2.22% increase. The content provided is primarily a placeholder for this financial filing, with minimal specific details about the 8K's contents. It indicates the document is available on Investing.com, which also provides various financial market data and related news.
Upstream Bio, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.73) — 10-Q Summary
Upstream Bio, Inc. reported its second-quarter 2026 results, showing revenue of $0.8M and a net loss of $39.7M, resulting in a diluted EPS of $(0.73), which is largely consistent with the previous year. The company highlighted clinical progress for Verekitug in severe asthma and CRSwNP, with plans to initiate Phase 3 trials in Q1 2027. Upstream Bio also noted increased R&D spending and a collaboration with Maruho for commercialization rights in Japan.
Upstream Bio (NASDAQ: UPB) reports Q2 2026 loss and advances Phase 3 plans
Upstream Bio (NASDAQ: UPB) reported a Q2 2026 net loss of $39.7 million, similar to the previous year, with cash reserves of $261.3 million expected to fund operations through 2027. The company is advancing its lead asset, verekitug, towards Phase 3 trials for severe asthma and CRSwNP in Q1 2027, and has completed enrollment for its Phase 2 COPD trial. Positive Phase 2 data for verekitug in CRSwNP and severe asthma continue to reinforce its potential for best-in-class efficacy with convenient quarterly dosing.
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
Upstream Bio announced its second-quarter 2026 financial results, highlighting significant progress in developing verekitug for severe inflammatory respiratory diseases. The company is on track to initiate Phase 3 trials for severe asthma and CRSwNP in Q1 2027 and has completed enrollment for its Phase 2 VENTURE trial in COPD, with data expected in the second half of 2027. Upstream Bio also reported cash, cash equivalents, and short-term investments of $261.3 million, sufficient to fund operations through 2027.
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
Upstream Bio reported its second-quarter 2026 financial results, highlighting significant progress in advancing verekitug for severe asthma, CRSwNP, and COPD. The company is on track to initiate Phase 3 trials for severe asthma and CRSwNP in Q1 2027 and has completed enrollment for its Phase 2 VENTURE trial in COPD, with data expected in H2 2027. Financially, Upstream Bio reported cash, cash equivalents, and short-term investments of $261.3 million, sufficient to fund operations through 2027.
Arrowstreet Capital Limited Partnership Buys New Holdings in Upstream Bio, Inc. $UPB
Arrowstreet Capital Limited Partnership has acquired 185,087 shares of Upstream Bio, Inc. (NASDAQ:UPB) for approximately $1.67 million, representing a new holding in the company. Despite reporting a quarterly loss of $0.75 per share, matching revenue forecasts, Upstream Bio faces mixed analyst sentiment with a "Hold" rating and a consensus price target of $33.17, significantly above its current trading price of $6.74 near its 52-week low. The biotech company, focused on next-generation prophylactic vaccines and immuno-oncology therapies, has seen other institutional investors also adjust their stakes.
Upstream Bio Inc (UPB) Earnings Forecast: Future EPS & Revenue Growth Estimates
Upstream Bio Inc (UPB) has an earnings forecast score of 7.78, ranking 268th in the Biotechnology & Medical Research industry. Analysts project an average price target of $43.00, with a strong "Buy" rating based on 9 analysts. The company's expected revenue for the next quarter is $430.71K, and the EPS for the previous quarter was -$2.66, with an expectation of -$0.76 for the upcoming quarter.
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Hold" from Analysts
Seven analysts currently covering Upstream Bio (NASDAQ:UPB) have given the company a consensus "Hold" rating, with an average 12-month price target of $33.17, significantly above its current trading price of $6.57. The clinical-stage biotech recently reported a quarterly loss of $0.75 per share, missing estimates, but its revenue matched expectations. Despite some institutional investors increasing their stakes, the stock is trading near its one-year low, and analysts anticipate a full-year loss of approximately $2.90 per share.
Upstream Bio Inc (UPB) Financial Health: Profitability & Balance Sheet Analysis
Upstream Bio Inc (UPB) has a current financial score of 7.08, placing it 156th out of 384 companies in the Biotechnology & Medical Research industry, indicating a robust financial status but low operating efficiency. The company's latest quarterly revenue saw an 82.69% year-over-year increase, with net profit rising by 48.85%. Despite growth in revenue and profit, several key financial metrics like cash and cash equivalents, operating profit, and free cash flow for various dimensions are not yet disclosed by the company.
Upstream Bio Inc (UPB) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Upstream Bio Inc (UPB), noting its current valuation score of 8.10 within the Biotechnology & Medical Research industry. It details UPB's P/E ratio, highlighting its position relative to recent highs and lows. The analysis also states that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Upstream Bio Inc (UPB) Cash Flow
This article provides a detailed cash flow statement for Upstream Bio Inc (UPB), covering quarterly and annual data for operating, investing, and financing activities. It presents key financial figures such as net income, capital expenditures, and free cash flow, along with year-over-year percentage changes. The article also includes an FAQ section explaining different types of cash flow and their significance for investors.
UPB|Upstream Bio Inc|Price:6.400|Chg%:-0.010
Upstream Bio Inc. (UPB) is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, specifically severe respiratory disorders. The company's primary candidate, verekitug, targets the TSLP receptor and is currently in Phase II trials for severe asthma and chronic rhinosinusitis with nasal polyps, with plans to expand into COPD. This article provides a detailed company profile, including financial data, market performance, executive team, and institutional shareholding information.
Upstream Bio Inc (UPB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Upstream Bio Inc (UPB), though notes that detailed segment and profit contribution data have not yet been disclosed by the company. It highlights that the company's reported revenue of $2.85 million originates entirely from the United States. The report includes current stock metrics and a link to company financials and discussions.
Upstream Bio Inc (UPB) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Upstream Bio Inc (UPB), identifying major institutional holders and their respective proportions. It breaks down shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity including changes in holdings. Additionally, it lists ETFs with exposure to Upstream Bio Inc.
UPB|Upstream Bio Inc|Price:6.400|Chg%:-0.010
Upstream Bio Inc (UPB) has a strong financial health and high growth potential, though its valuation is considered fair. Analysts have a "Buy" rating with an average target price significantly above its current trading price, and institutional ownership is substantial. The company focuses on developing treatments for inflammatory diseases, with its primary drug verekitug in Phase II trials for severe asthma and chronic rhinosinusitis.
TradingKey
This article provides a detailed quarterly and annual income statement for Upstream Bio Inc (UPB), covering various financial metrics such as revenue, operating expenses, net income, and EPS. It also includes an FAQ section explaining how to interpret income statements and highlighting key financial figures for the company, such as its revenue and net income for recent periods.
Enterprise value to revenue forward of Upstream Bio, Inc. – NASDAQ:UPB
This article focuses on the enterprise value to revenue forward metric for Upstream Bio, Inc. (NASDAQ: UPB). It provides a snapshot of this financial ratio sourced from TradingView, indicating the value and any changes over a given period. The content is presented within the framework of market data and financial analysis tools.
Upstream Bio (Nasdaq:UPB) - Stock Analysis
Upstream Bio (Nasdaq:UPB) is a clinical-stage biotechnology company focused on treating inflammatory diseases, particularly severe respiratory disorders, with its lead asset verekitug. The company recently presented positive Phase 2 data for verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, demonstrating clinically meaningful improvements. Despite being unprofitable with declining earnings forecasts, analysts updated price targets and revenue estimates, anticipating Phase 3 trial initiations in 2027.
ETFs Investing in Upstream Bio, Inc. Stocks
This article lists various ETFs that hold shares of Upstream Bio, Inc. (UPB), providing details such as market value, weight in the ETF, issuer, management style, expense ratio, AUM, price, and performance metrics. The information aims to help investors identify funds that offer exposure to Upstream Bio, Inc. stock at potentially lower risk and with more opportunities.
Price to earnings forward of Upstream Bio, Inc. – NASDAQ:UPB
This article provides the "Price to earnings forward" metric for Upstream Bio, Inc. (NASDAQ: UPB) as listed on TradingView. It indicates that the market was closed with no trades recorded at the time of data retrieval. The report presents the value and percentage change for this financial metric.
Price to book forward of Upstream Bio, Inc. – NASDAQ:UPB
This article provides the "Price to book forward" value for Upstream Bio, Inc. (NASDAQ: UPB). It includes basic financial information and indicates that the market was closed with no trades at the time of publication. The data is presented within the context of a financial markets platform.
UPB - Upstream Bio Inc Dividends
This article provides detailed financial data and performance metrics for Upstream Bio Inc. (UPB). It lists various financial ratios, stock performance over different periods, insider and institutional ownership, and analyst recommendations, noting that the company does not currently pay dividends. The report covers essential investment-related information without offering a narrative.
Price to sales forward of Upstream Bio, Inc. – NASDAQ:UPB
The article focuses on the "Price to sales forward" metric for Upstream Bio, Inc. (NASDAQ: UPB). It provides a snapshot of the company's financial data on TradingView, indicating that the market was closed at the time of viewing. The content is primarily a data point with no further detailed analysis or commentary.
If You Invested $1,000 in UpStream Bio Inc. (UPB)
This article examines the historical performance of a $1,000 investment in UpStream Bio Inc. (UPB), a clinical-stage biotechnology company focused on inflammatory diseases. It provides detailed information on UPB's core drug candidate, verekitug, its mechanism of action, and its progress through Phase 2 clinical trials for conditions like CRSwNP, severe asthma, and COPD. The content includes financial data, year-by-year returns, and comparative analysis with the S&P 500.
Here's Why We're Watching Upstream Bio's (NASDAQ:UPB) Cash Burn Situation
This article examines Upstream Bio's cash burn rate and its implications for the company's future operations. It analyzes the current cash reserves against the burn rate to estimate how long the company can continue funding its activities without additional capital. The article highlights the importance of managing cash burn for biotechnology companies in the clinical development phase.
Enterprise value to EBIT forward of Upstream Bio, Inc. – NASDAQ:UPB
The article focuses on the enterprise value to EBIT forward ratio for Upstream Bio, Inc., trading under the NASDAQ symbol UPB. It appears to be a financial data point presented within a trading platform context, with placeholders for actual financial figures.
Upstream Bio, Inc. Actuals & Estimates (NASDAQ:UPB)
This article provides an overview of Upstream Bio, Inc. (NASDAQ: UPB) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details key financial actuals and estimates such as earnings per share and revenue, indicating the company's next earnings report is due on August 12, 2026.
Upstream Bio, Inc. (UPB) reports Q1 loss, beats revenue estimates
Upstream Bio, Inc. (UPB) reported a Q1 loss per share of $0.93, which was lower than the analyst estimate of a $1.09 loss per share. The company also announced Q1 revenue of $180,000, surpassing the analyst consensus estimate of $170,000.
Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?
Upstream Bio, Inc. (NASDAQ:UPB) is highlighted as a promising small-cap stock following new analyst coverage from H.C. Wainwright, which initiated a Buy rating and a $36 price target. The analyst praised the company's lead candidate, verekitug, an antibody targeting the thymic stromal lymphopoietin receptor, for its potential efficacy and differentiated quarterly subcutaneous dosing. Additionally, Upstream Bio recently presented positive Phase 2 VIBRANT trial results for verekitug in chronic rhinosinusitis with nasal polyps, showing clinically meaningful reductions in nasal polyp scores.
